ERT offers centralized cardiac safety and respiratory efficacy services in drug development and also collects, analyzes and distributes ePRO in multiple modalities across all phases of clinical research.
A specialty division of a pharmaceutical company has awarded $7m contract to ERT to manage a suite of studies using ERT’s proprietary VIAPhone platform over the next three years.
ERT will also provide VIAPen solution for a pivotal Phase III program, under a $3m contract.
ERT will also allow a pharma company to use its VIAPhone Pain Diary for a Phase III clinical trial, along with VIAPen solution for site assessments, as part of a $1.2m contract.